A two‐phase epigenome‐wide four‐way gene–smoking interaction study of overall survival for early‐stage non‐small cell lung cancer

Leyi Chen,Xiang Wang,Ning Xie,Zhongwen Zhang,Xiaowen Xu,Maojie Xue,Yuqing Yang,Liya Liu,Li Su,Maria Bjaanæs,Anna Karlsson,Maria Planck,Johan Staaf,Åslaug Helland,Manel Esteller,David C. Christiani,Feng Chen,Ruyang Zhang

DOI: https://doi.org/10.1002/1878-0261.13766

2024-12-06

Molecular Oncology

Abstract:This study identifies a four‐way interaction among smoking pack‐years and three DNA methylation probes (cg05293407TRIM27, cg00060500KIAA0226, and cg16658473SHISA9) associated with NSCLC survival. This interaction improves the model's ability to predict survival outcomes, offering new insights into molecular mechanisms of NSCLC progression and potential therapeutic targets. High‐order interactions associated with non‐small cell lung cancer (NSCLC) survival may elucidate underlying molecular mechanisms and identify potential therapeutic targets. Our previous work has identified a three‐way interaction among pack‐year of smoking (the number of packs of cigarettes smoked per day multiplied by the number of years the person has smoked) and two DNA methylation probes (cg05293407TRIM27 and cg00060500KIAA0226). However, whether a four‐way interaction exists remains unclear. Therefore, we adopted a two‐phase design to identify the four‐way gene–smoking interactions by a hill‐climbing strategy on the basis of the previously detected three‐way interaction. One CpG probe, cg16658473SHISA9, was identified with FDR‐q ≤ 0.05 in the discovery phase and P ≤ 0.05 in the validation phase. Meanwhile, the four‐way interaction improved the discrimination ability for the prognostic prediction model, as indicated by the area under the receiver operating characteristic curve (AUC) for both 3‐ and 5‐year survival. In summary, we identified a four‐way interaction associated with NSCLC survival among pack‐year of smoking, cg05293407TRIM27, cg00060500KIAA0226 and g16658473SHISA9, providing novel insights into the complex mechanisms underlying NSCLC progression.

oncology